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WeusedSurveillance,Epidemiology,andEnd
Results–Medicaredata(2000–2006)todescribetreatmentand
survivalinwomendiagnosedwithmetastaticbreastcancer
(MBC)whoreceivedtrastuzumab.Therewere610patientswith
ameanageof74years.Overall,32%receivedtrastuzumab
aloneand47%receivedtrastuzumabplusataxane.In
multivariateanalysis,trastuzumabpluschemotherapywas
associatedwithaloweradjustedcancermortalityrate(Hazard
Ratio[HR]0.54;95%ConﬁdenceInterval[CI]0.39–0.74;p<
.001)thantrastuzumabaloneamongpatientswhoreceived
trastuzumabaspartofﬁrst-linetherapy.Addingchemotherapy
toﬁrst-linetrastuzumabformetastaticbreastcanceris
associatedwithimprovedcancersurvival.
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INTRODUCTION
In metastatic breast cancer (MBC) among patients with
human epidermal growth factor receptor 2 (HER2) over-
expressing disease, trastuzumab is indicated for use in
combination with paclitaxel for first-line treatment, and
a sas i n g l ea g e n tf o rt h o s ew h oh a v ep r e v i o u s l yr e c e i v e d
one or more chemotherapy regimens (1). The safety and
efficacy of trastuzumab in MBC have been evaluated in
numerous clinical trials (2–10). Two were particularly
relevant for establishing the current indication in MBC (1).
One was a multicenter, randomized, open-label trial con-
ducted in 469 women who had not been previously treated
with chemotherapy for metastatic disease (1, 8). In this
trial, patients were randomly assigned to receive standard
chemotherapy alone (n = 234) or standard chemotherapy
plus trastuzumab (n = 235). Standard chemotherapy con-
sisted of doxorubicin (or epirubicin) and cyclophosphamide
forwomenwhohadnotpreviouslyreceivedadjuvanttherapy
with an anthracycline, or paclitaxel for women previously
treated with an anthracycline (average age 52 years, ranging
from 25 to 77). Adding trastuzumab to standard chemother-
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apy was associated with a lower rate of death at one year (22
versus 33%, p = .008), a longer survival (median survival,
25.1versus20.3months,p =.046)time,anda20%reduction
in the risk of death (8). The other study was a multicenter,
open-label, single-arm clinical trial in 222 women who had
relapsed following one or two prior chemotherapy regimens
for metastatic disease (1, 4). In this trial, trastuzumab was
studied as a single agent in a population with an average age
of 50 years, ranging from 28 to 81 (4). The objective tumor
response, as determined by an independent response evalu-
ation committee, was 15% in the intent-to-treat group (4).
Although trastuzumab for MBC has been studied ex-
tensively in clinical trials, little has been published on its
use in routine clinical practice, especially in populations
underrepresented in the trials. Despite the fact that HER2-
positivediseasehasayoungeragedistribution,olderpatients
still comprise a significant proportion of those who might
be eligible to receive trastuzumab for MBC. According to
the Surveillance, Epidemiology, and End Results (SEER)
program, 57% (n = 4,179) of the 7,331 women diagnosed
with Stage IV breast cancer in 2004–2006 were aged 65 years
or older (11). The objectives of this study were to describe
patterns of infused therapy in a cohort of older women who
first received trastuzumab following diagnosis of MBC, and
to identify factors associated with longer survival.
MATERIAL AND METHODS
Datasource
The source of data for this study was the National Can-
cer Institute’s (NCI) SEER cancer registry linked to Medi-
care enrollment and claims data (SEER-Medicare data). This
database has been described in detail elsewhere (12). Briefly,
as of 2010, SEER collects and publishes cancer incidence
and survival data from 17 population-based cancer registries
throughout the United States covering approximately 26%
of the US population (13). The registries routinely collect
data on patient demographics, primary tumor site, tumor
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morphology and stage at diagnosis, first course of treatment,
and follow-up for vital status. In the SEER-Medicare data,
for persons age 65 years or older, 97% are eligible for Medi-
care,and93%ofpatientsintheSEERfilesarematchedtothe
Medicareenrollmentfile(14).Atthetimethisstudywasper-
formed, the SEER-Medicare linkage included all Medicare-
eligiblepersonsfrom16ofthe17registriesthrough2005and
their Medicare claims for Part A (inpatient) and Part B (out-
patient and physician services) through 2006.
Patienteligibility
Patients were included in this study if they were diagnosed
withMBC,definedaseither(A)denovoStageIVbreastcan-
cerbetween2000and2005,or(B)denovo Stage0–III breast
cancer between 2000 and 2005, with a distant recurrence
before the end of their Medicare claims. Distant recurrence
was identified by an International Classification of Diseases,
9th Revision, Clinical Modification (ICD-9-CM) code in the
medical claims for secondary cancer (197.XX–198.XX), ex-
cluding in the breast (198.81, 198.82) or in the lymph nodes
(196.XX) based on algorithms for identifying cancer relapse
previously reported in the literature (15, 16). These algo-
rithms were originally developed for detecting relapse of
acute myelogenous leukemia (AML), and the best among
them showed a sensitivity of 86% and a specificity of 99%
in this disease (15). More recently, they have been applied
to, but not validated in, a study on the costs of breast cancer
recurrence (16). Other inclusion criteria consisted of the fol-
lowing:breastcancerwasthefirstprimarycancerdiagnosed;
patients first received trastuzumab therapy after diagnosis of
M B C ;a n dp a t i e n t sw e r ee n r o l l e di nM e d i c a r eP a r t sAa n dB ,
with no health maintenance organization (HMO) coverage
for 12 months prior to de novo diagnosis of breast cancer.
Patients were excluded for any of the following reasons:
malegender;trastuzumabusepriorto diagnosisofMBC; de
novo diagnosis of breast cancer before age of 65 years; diag-
nosis made by death certificate or autopsy; death within the
first month following diagnosis; or Medicare enrollment less
than 12 months before diagnosis.
Treatments
For purposes of describing treatment patterns, the observa-
tion period was defined as beginning on the day MBC was
diagnosed (the index date) and ending on the last day of
Medicare claims (December 31, 2006) or death, whichever
came first. Since, for confidentiality reasons, SEER provides
only the calendar month in which cancer is diagnosed, for
de novo S t a g eI Vp a t i e n t s ,t h ed a t eo fM B Cd i a g n o s i sw a s
defined as the first day of the calendar month in which they
were diagnosed with breast cancer. For de novo Stage 0–III
patients, the date of diagnosis was defined as the date of
the first Medicare claim indicating distant recurrence. ICD-
9-CM procedure codes (17) and Healthcare Common Pro-
cedure Coding System (HCPCS) codes (18) within Medi-
care claims were used to identify intravenous chemotherapy
agentsandtrastuzumabadministeredduringtheobservation
period (19, 20).
In addition to de novo Stage, patients were further clas-
sified according to whether trastuzumab was part of their
first infused therapy regimen during the observation period
(first-line trastuzumab), or whether it was started after an
initial course of chemotherapy during the observation pe-
riod (delayed trastuzumab) (Figure 1). If trastuzumab began
Patients who received trastuzumab for metastatic breast cancer 
(N = 610a)
De novo diagnosisbof Stage IV disease
(n = 254 [42%])
First-lined
trastuzumab
(n = 173 [68%])
With 
Chemotherapy
(n = 132 [76%])
Without 
Chemotherapy
(n = 41 [24%])
Delayede
trastuzumab
(n = 81 [32%])
With 
Chemotherapy
n = 52 [64%])
Without 
Chemotherapy
(n = 29 [36%])
De novo diagnosisbof Stage 0-III disease 
followed by a distant recurrencec
(n = 356 [58%])
First-lined
trastuzumab
(n = 252 [71%])
With 
Chemotherapy
(n = 160 [63%])
Without 
Chemotherapy
(n = 92 [37%])
Delayede
trastuzumab
(n = 104 [29%])
With 
Chemotherapy
(n = 68 [65%])
Without 
Chemotherapy
(n = 36 [35%])
Figure1.Studypopulation. aTotalnumberofpatientsmeetingtheinclusionandexclusioncriteriaforthestudy. bDenovostagingaccordingtoSEER.
cIdentification of distant recurrence according to Medicare claims. dTrastuzumab part of the first treatment regimen after diagnosis of metastatic
breast cancer. eTrastuzumab part of second or subsequent treatment after diagnosis of metastatic breast cancer.
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within two months of the first claim for chemotherapy, or
if there was no chemotherapy claim present, the patient was
classified as having received first-line trastuzumab. This reg-
imen was then classified hierarchically using ICD-9-CM and
HCPCS codes as follows: trastuzumab alone; trastuzumab
plus a taxane (paclitaxel or docetaxel), with or without any
other agent; and trastuzumab with any other agent except
a taxane. Assignment was based on having had at least one
claim for each agent during two of the first 6 months follow-
ing the first chemotherapy claim.
If trastuzumab began at least 2 months after the first
claim for chemotherapy, the patient was classified as having
received delayed trastuzumab (Figure 1). In this group, the
initial chemotherapy regimen (absent trastuzumab) was
classified, using the same approach above, as: anthracycline
and/or cyclophosphamide with or without any other agent;
taxane and/or vinorelbine with any other agent except an-
thracyclineorcyclophosphamide;andother.Thesubsequent
regimen that included trastuzumab was classified the same
way as the first-line trastuzumab group described above.
Visual inspection of the data prior to the development of
this classification scheme showed that in the group receiving
delayed trastuzumab, there was very little overlap between
the agents used in the initial chemotherapy regimen and
t h o s eu s e di nt h es u b s e q u e n tt r a s t u z u m a br e g i m e n .
Medicare Part D (prescription drug coverage) data were
n o ta v a i l a b l ea tt h et i m et h i ss t u d yw a sp e r f o r m e d .C o n s e -
quently, it was not possible to identify anti-estrogen or other
oral therapy use in this population.
Mortalityandcensoring
T h ed a t eo fd e a t hw a sa s s i g n e db yu s i n gt h eM e d i c a r ed a t e ,
if available, even in cases where the SEER date also was
available. The Medicare date was preferred because it is more
currentthantheSEERdate(21).IncaseswheretheMedicare
date was missing but the SEER date of death was available,
the SEER date was used. All other patients were assumed
t ob ea l i v ea tt h ee n do ft h eo b s e r v a t i o np e r i o d( D e c e m b e r
31, 2006), although they may have been censored earlier
for other reasons, such as switching from fee-for-service to
HMO coverage.
The cause of death was classified as cancer or noncancer,
using the CODKM variable in the SEER Patient Entitlement
andDiagnosisSummaryFile(PEDSF)through2006.Cancer
mortality included all deaths due to cancer (CODKM =
001–130), and not just due to breast cancer (CODKM =
046). Noncancer mortality included all other identified
causesofdeath,e.g.,CODKM =154“DiseasesofHeart”and
CODKM = 148 “Diabetes Mellitus”. However, it excluded
m i s s i n go ru n s p e c i f i e dc a u s eo fd e a t h .T h e s ep a t i e n t sw e r e
censored at the time of death in both the cancer and non-
cancer survival analysis since exploratory analysis showed
that almost 90% of those with a known cause of death
died of cancer. Consequently, including them as noncancer
deaths could have resulted in significant misclassification.
Cancer and noncancer mortality were examined separately
since the benefit of cancer therapy should be manifested
primarily through differences in cancer mortality, and
differences in noncancer mortality could indicate selection
bias, particularly confounding by indication (22).
Patientcharacteristics
Patients were described according to their demographic and
clinical characteristics at the time MBC was diagnosed, with
the exception of calculating the NCI Comorbidity Index (23)
(described below), which was done at the time of de novo
breast cancer diagnosis. Patient age at MBC diagnosis was
stratified into five groups: 66–69; 70–74; 75–79; 80–84; and
≥85. Requiring eligible patients to have at least one year
of Medicare enrollment prior to diagnosis ensured that the
minimum age in the cohort was 66 years. Race/ethnicity
was defined using the SEER recoded race variable as white,
black, Hispanic, and other (which consists predominantly of
American Indian/Native Alaskan, Native Hawaiian or Other
Pacific Islander, and Asian) (24).
Medicare inpatient (Part A), outpatient, and physician
( P a r tB )c l a i m sw e r eu s e dt oc a l c u l a t ea nN C IC o m o r b i d i t y
Index for each patient (23). This approach (25, 26) entailed
first removing claims that were considered to have unreli-
able diagnosis coding, such as those for testing procedures
used to rule out conditions. Then, remaining diagnosis and
procedure codes were used to identify the 15 noncancer co-
morbidities in the Charlson Comorbidity Index (CCI) (27).
The algorithms used to identify these conditions reflect the
Deyo (28) adaptation of the CCI, and include several proce-
dure codes from the Romano (29) adaptation. A weight was
assigned to each condition, and the weights were summed to
obtain the index for each patient.
In the absence of performance status, we used Medicare
claims to construct several medical resource utilization vari-
a b l e st h a th a v eb e e ns h o w na n dv a l i d a t e dt op r e d i c tp e r -
formance status, (30) consisting of any inpatient admission
(yes/no),anyadmissiontotheemergencyroom(yes/no),any
use of durable medical equipment (yes/no), and any outpa-
tient visit (yes/no) from 12 months before to 1 month after
the diagnosis of MBC. In addition, we used SEER data and
Medicare claims to identify prior surgery for breast cancer
and radiation treatment (20, 31).
Statisticalanalysis
Cox proportional hazards regression analysis was used
to identify treatment, demographic, and clinical factors
associated with overall survival. Multivariate analyses were
performed on all-cause, cancer and noncancer mortality, in-
cluding the entire cohort and stratified according to whether
the patient received first-line or delayed trastuzumab (total
of9analyses).W eelectedtoconductstratifiedanalysesoutof
concern that these two groups might have significantly dif-
ferent prognostic features that could confound associations
between treatment and survival in a single model.
Inadditiontothestandardapproachtomultivariateanal-
yses,whichincludedindividualpredictors,multivariateanal-
yses were performed using propensity techniques, (32) in
which quintile of propensity score was substituted for all in-
dependent variables except initial trastuzumab regimen (to-
tal of 9 analyses), and in which the inverse of the propensity
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score was used as a weight in the regression analysis (total of
9a n a l y s e s ) .
Since treatment with trastuzumab following MBC diag-
nosis was a criterion for inclusion in this study, one concern
in specifying this analysis was to avoid immortal time bias,
(33)which,accordingtoSuissa,is“aspanofcohortfollow-up
during which, because of exposure definition, the outcome
under study could not occur.” In this case, death could not
occurbetweenthetimethepatientwasdiagnosedwithMBC
a n dt h et i m et h ep a t i e n tf i r s tr e c e i v e dt r a s t u z u m a b .T h e r e -
fore, the index date for this analysis was advanced from the
dateofdiagnosisto30daysafterthedateofthefirstclaimfor
trastuzumab, to account also for the fact that additional time
was required to determine whether or not patients received
chemotherapy as part of their initial trastuzumab regimen.
RESULTS
CharacteristicsofPatients
There were 610 patients who met the study inclusion crite-
ria (Table 1). Of these, 58% were diagnosed with Stage 0–III
disease with a distant recurrence, while the remaining pa-
tients were diagnosed with de novo Stage IV disease. The
medianageatthetimeofMBCdiagnosiswas73years(mean
74years),and22%wereage80yearsorolder.Thosewhohad
adistantrecurrenceafterbeingdiagnosedwithdenovoStage
0–III disease were significantly older (p < .0001). The mean
timefromdenovodiagnosisofbreastcancertorecurrencein
thisgroupwas17months(median13months).Themajority
of patients were white race. However, those diagnosed with
de novo Stage IV disease were more likely to be nonwhite
(p = .03). Less than half of the patients were estrogen recep-
tor (ER)—and/or progesterone receptor (PR)—positive, and
differences in hormone status between the two groups were
notstatisticallysignificant.Mostpatientshadnoneoftheco-
morbidities in the NCI Comorbidity Index. Finally, almost
all patients in the de novo Stage 0–III group had surgery for
breast cancer within 4 months of diagnosis, compared with
less than 50% with de novo Stage IV disease.
PatternsofTrastuzumabUse
The mean time to initial trastuzumab following diagnosis of
MBC was almost 6 months, with a median time of 2 months
(Table 2). The median time in the de novo Stage 0–III with
distant recurrence group was half that of the Stage IV group.
However, the mean times were similar. The average dura-
tion of trastuzumab was 13 months, and it was significantly
longer for those diagnosed with de novo Stage IV disease
(16 months) compared with denovo Stage 0–III with distant
recurrence (11 months). During trastuzumab therapy, pa-
tients received an average of 2.1 administrations per month,
and there were very few calendar months during the course
of therapy (6%) in which patients did not receive at least one
administration of trastuzumab.
Table 1. Patient Characteristics
De Novo Stage of Breast Cancera
Stage 0–III (n = 356) Stage IV (n = 254) All Patients (n = 610) p Valueb
Age at diagnosis of metastatic
breast cancer
66–69 51 14.3% 73 28.7% 124 20.3% <.0001
70–74 121 34.0% 74 29.1% 195 32.0%
75–79 88 24.7% 67 26.4% 155 25.4%
80–84 69 19.4% 27 10.6% 96 15.7%
≥85 27 7.6% 13 5.1% 40 6.6%
Race/ethnicity White 298 83.7% 191 75.2% 489 80.2% .03
Black 30 8.4% 39 15.4% 69 11.3%
Hispanic 16 4.5% 11 4.3% 27 4.4%
Other 12 3.4% 13 5.1% 25 4.1%
Year of metastatic breast cancer
diagnois
2000 16 4.5% 28 11.0% 44 7.2% <.0001
2001 41 11.5% 37 14.6% 78 12.8%
2002 46 12.9% 34 13.4% 80 13.1%
2003 50 14.0% 42 16.5% 92 15.1%
2004 69 19.4% 66 26.0% 135 22.1%
2005–2006 134 37.6% 47 18.5% 181 29.7%
Estrogen(ER) and progesterone
(PR) receptor status
ER+ and PR+ 83 23.3% 68 26.8% 151 24.8% .54
ER+ or PR+ 55 15.4% 42 16.5% 97 15.9%
ER− and PR− or
unknown
218 61.2% 144 56.7% 362 59.3%
National Cancer Institute
Comorbidity Index
0 313 87.9% 226 89.0% 539 88.4% .90
≥14 3 1 2 .1% 28 11.0% 71 11.6%
Prior surgery for breast cancer 342 96.1% 124 48.8% 466 76.4% <.0001
Radiation 192 53.9% 159 62.6% 351 57.5% 0.03
Prior inpatient admission 217 61.0% 114 44.9% 331 54.3% <.0001
Prior emergency department Visit 37 10.4% 27 10.6% 64 10.5% .93
Claim for durable medical
equipment
141 39.6% 46 18.1% 187 30.7% <.0001
aDe Novo Stage could be either Stage IV or Stage 0–III. However, all patients initially diagnosed with Stage 0–III had a distant recurrence documented in their Medicare claims to
be included in the study.
bAll tests of significance performed using Chi Square analysis. Comparisons are de novo Stage IV to de novo Stage 0–III.
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Table 2. Patterns of Trastuzumab use
De Novo Stage of Breast Cancera.
Stage 0–III (n = 356) Stage IV (n = 254) All Patients (n = 610) p Valueb.
Metastatic breast cancer diagnosis to
first trastuzumab (days)
Mean (SDc) 172.8 (304.5) 176.8 (227.0) 174.5 (274.7) .85
Median (IQRd) 42 (14–173) 78 (47–189) 63 (26–183)
Months of trastuzumab (months) Mean (SD) 11.0 (10.5) 15.7 (14.7) 12.9 (12.6) <.0001
Median (IQR) 8.0 (3.0–15.0) 12.0 (4.0–22.0) 10.0 (4.0–18.0)
Trastuzumab administrations per
month
Mean (SD) 2.1 (1.0) 2.1 (1.0) 2.1 (1.0) .30
Median (IQR) 2 (1.1–2.9) 2.0 (1.25–3.0) 2.0 (1.16–3.0)
aDe novo Stage could be either Stage IV or Stage 0–III. However, all patients initially diagnosed with Stage 0–III had a distant recurrence documented in their Medicare claims to
be included in the study.
bAll tests of significance performed on means using t-test. Comparisons are de novo Stage IV to de novo Stage 0–III.
cSD—Standard deviation.
dIQR—Interquartile range.
Overall, 70% of the cohort received first-line trastuzumab
(Table3).Theproportionofpatientsdiagnosedwithdenovo
Stage IV disease was similar between patients who received
f i r s t - l i n ea n dt h o s ew h or e c e i v e dd e l a y e dt r a s t u z u m a b .M o s t
first-line trastuzumab patients received either monotherapy
(31%) or trastuzumab plus a taxane (48%) as initial ther-
a p yf o l l o w i n gM B Cd i a g n o s i s .I nt h ed e l a y e dt r a s t u z u m a b
group, a slightly higher proportion of patients received
trastuzumab alone (35%), and a slightly lower proportion
received trastuzumab plus a taxane (45%) relative to first-
line trastuzumab patients. During the observation period
(2000–2006), the percent of patients receiving trastuzumab
alone varied from 23 (2000) to 38% (in both 2003 and 2006).
Longitudinal “lasagna” plots (34) were constructed to il-
lustrate the number of administrations of trastuzumab per
month, the duration of trastuzumab, and gaps in adminis-
tration (Figure 2) for up to 24 months following the start of
treatment. These were stratified by de novo stage and first-
line versus delayed use. In general, there was a broad spec-
trum of use in all four groups, ranging from uninterrupted
treatment in excess of one year with four or more adminis-
trations in each month, to treatment lasting only one month
with only one administration.
SurvivalAnalysis
Overall, 345 (57%) patients died during the observation pe-
riod: 281 (81%) of these had cancer listed as the cause of
death; 24 (7%) had a noncancer cause of death; and the re-
maining 40 (12%) had no cause of death listed and were
censored in the cause-specific, but not the overall survival
analysis. The estimated median survival was 566 days (95%
Confidence Interval [CI] 495–644) in the entire cohort, 564
days (95% CI 473–644) in those who received first-line
trastuzumab, and 579 days (95% CI 454–788) in those who
received delayed trastuzumab.
In multivariate analysis that included the entire cohort,
(Table 4) trastuzumab plus chemotherapy was associated
withstatisticallysignificantlylowercancermortality(Hazard
Ratio [HR] 0.67; 95% CI 0.51–0.88; p < .01), but not non-
cancer mortality.
In stratified analysis, (Table 5) first-line trastuzumab
plus chemotherapy was associated with statistically
significantly lower cancer mortality (HR 0.54; 95% CI
0.39–0.74; p < .001). However, adding chemotherapy to
d e l a y e dt r a s t u z u m a bh a dn oi m p a c to nc a n c e rm o r t a l i t y .
Findings from the propensity score analysis were consistent
with those from the standard regression analysis (Figure 3).
Table 3. Trastuzumab Regimens
De Novo Stage of Breast Cancera
Treatment Regimens Stage 0–III (n = 356) Stage IV (n = 254) All Patients (n = 610) p Valueb
First-line trastuzumab (70% of cohort) 59.3 (252) 40.7 (173) 100 (425)
Trastuzumab regimen [%(n)] .02
Trastuzumab alone 36.5 (92) 23.7 (41) 31.3 (133)
Trastuzumab plus taxane 44.4 (112) 53.2 (92) 48.0 (204)
Trastuzumab plus other 19.1 (48) 23.1 (40) 20.7 (88)
Delayed Trastuzumab (30% of cohort) 56.2 (104) 43.8 (81) 100 (185) .07
Initial chemotherapy regimen [%(n)]
Anthracycline and/or cyclophosphamide 41.4 (43) 56.8 (46) 48.1 (89)
Taxane and/or vinorelbine 19.2 (20) 18.5 (15) 18.9 (35)
Other (neither of the above) 39.4 (41) 24.7 (20) 33.0 (61)
Trastuzumab Regimen [%(n)] .71
Trastuzumab alone 34.6 (36) 35.8 (29) 35.1 (65)
Trastuzumab plus taxane 43.3 (45) 46.9 (38) 44.9 (83)
Trastuzumab plus other 22.1 (23) 17.3 (14) 20.0 (37)
aDe novo Stage could be either Stage IV or Stage 0–III. However, all patients initially diagnosed with Stage 0–III had a distant recurrence documented in their Medicare claims to
be included in the study.
bAll tests of significance performed using Chi Square analysis. Comparisons are de novo Stage IV to de novo Stage 0–III.
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Figure 2. Patterns of trastuzumab use. Each row of data represents a single patient. Each colored rectangle within each row represents one month,
ordered chronologically following the beginning of trastuzumab therapy, up to a maximum of 24 months. Dark blue rectangles indicate more
administrations of trastuzumab in that month; light blue rectangles indicate fewer administrations; orange rectangles indicate no administrations
of trastuzumab while the patient was still observed in the data set; and clear rectangles indicate that the patient was no longer observed in the data
because of death or the end of the observation period. Within each of the four figures, patients are ordered from high (top of figure) to low number
of trastuzumab administrations during 48 months following the beginning of therapy, a measure of both the intensity and duration of trastuzumab
therapy. MBC—Metastatic breast cancer
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Figure 3. Sensitivity of trastuzumab hazard ratio to changes in the multivariate survival analysis. This figure presents the results of three sets (all
patients, patients receiving first-line trastuzumab, patients receiving delayed trastuzumab) of nine multivariate survival analyses (three each for
all-cause, cancer, and noncancer mortality) designed to test the sensitivity of the findings reported in Tables 4 and 5 to changes in the approach
to multivariate analysis. Standard multivariate survival analyses (S) were performed with all individual patient variables included in the model.
Propensity multivariate survival analyses were performed with either propensity score quintile (PQ) included in the model as a substitute for
all patient variables except trastuzumab plus chemotherapy, or using propensity score as a weight (PSW). The y-axis indicates the hazard ratio for
trastuzumabpluschemotherapycomparedwithtrastuzumabalone.Trianglesrepresenttheestimatedhazardratiofortrastuzumabpluschemother-
apycomparedwithtrastuzumabalonefromthecorrespondingmodelonthex-axis.Barsaroundeachtrianglerepresenttheupperandlowerbounds
of the 95% confidence interval for the hazard ratio. Confidence intervals that overlap the horizontal line at the hazard ratio of 1.0 indicate that the
estimated hazard ratio for trastuzumab plus chemotherapy is not significant at p = .05.
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DISCUSSION
We conducted a study using SEER-Medicare to identify
patterns of infused therapy and survival in a cohort of older
women who received trastuzumab therapy for MBC. Our
findings show that following diagnosis of MBC, 70% of
the cohort received first-line trastuzumab therapy, while
the remainder received delayed trastuzumab. As first-line
treatment in MBC, trastuzumab is indicated for use in com-
bination with paclitaxel (1). However, we found that almost
one-third of these older patients who received first-line
trastuzumab received it without infused chemotherapy. The
use of trastuzumab monotherapy first-line was more com-
mon in patients diagnosed with de novo Stage 0–III disease
and a distant recurrence, compared with de novo Stage IV
disease (37% versus 24%). This suggests that the decision
to select trastuzumab monotherapy versus trastuzumab in
combination with one or more chemotherapy agents may
have been influenced by prior use of chemotherapy in the
adjuvant setting. Also, since this study was conducted in
patients diagnosed with breast cancer from 2000–2005, the
discrepancy between the labeled indication and what we ob-
s e r v e dm a yw e l lr e f l e c tt h ei m p a c to ft w oi m p o r t a n tc l i n i c a l
trials of first-line trastuzumab monotherapy for MBC, (5, 7)
bothofwhichwerepublishedseveralyearsaftertrastuzumab
was approved by the Food and Drug Administration (FDA).
Overall, the results of the multivariate analysis show that
adding chemotherapy to trastuzumab improves survival in
patientswithMBC.Moredetailedexaminationindicatesthat
this is true only for those who received trastuzumab as first-
line therapy and for cancer mortality alone. The findings
were robust to several different analytic approaches, includ-
ing propensity techniques.
The finding that adding chemotherapy to first-line
trastuzumab was associated with improved survival relative
to trastuzumab alone raises important questions with regard
to the optimal treatment regimen in these patients. Accord-
ing to one recent review, (2) at the time the patients in our
study were treated there had not been a randomized study of
trastuzumab with or without chemotherapy. However, a re-
centlypublishedrandomizedtrialoftrastuzumabmonother-
apy versus trastuzumabplus docetaxel as first-line therapy in
MBC,(10)wasstoppedearlyafteraninterimanalysisshowed
a significantly lower mortality rate in the patients receiving
chemotherapy with trastuzumab (HR for survival 2.72 p =
.04).UponinvertingtheHRforsurvival,wefindthattheHR
for overall mortality (0.37) in this trial was similar to the HR
ratio for cancer mortality among patients receiving first-line
trastuzumab plus chemotherapy (0.54) in our study. There-
fore, our findings based on data from routine clinical prac-
tice appear to support the findings from this recent trial, and
suggest they apply to elderly patients.
The main limitation of this study, as with any obser-
vational study that compares the effects of alternative
interventions, is the possibility that patients were selected
into the treatment groups for reasons related to survival,
(22, 35, 36) and that we failed to account for these reasons in
our analyses. Although no approach completely eliminates
confounding by indication in observational studies, (36) we
took several steps to minimize its impact here. One possibil-
ity is that patients with poorer performance status or more
comorbiditywereselectedtoreceivetrastuzumabmonother-
apy due to concerns about the toxicity of chemotherapy.
(22) SEER-Medicare does not include performance status.
Consequently, using Medicare claims we constructed several
medical resource use variables that have been validated to
predict ECOG and Karnofsky performance status (30). Also,
we examined cancer and noncancer mortality based on the
rationale that any real benefit of cancer treatment should be
observed only through cancer-specific mortality, and that
differences in noncancer mortality suggest confounding by
indication(22).Inthisstudy,wefoundaddingchemotherapy
to trastuzumab was associated with a significantly lower rate
of cancer but not noncancer mortality.
Although the coefficients for trastuzumab plus
chemotherapy were similar for cancer and noncancer
mortality, it is important to note that only 24 patients (8% of
those with a known cause of death) had a noncancer cause
of death. Consequently, the coefficients in these models are
unstable and their direction and significance can be deter-
mined by a few individuals. Finally, we used two different
approaches to multivariate survival analysis: the standard
approach in which all patient characteristics were included
as independent variables, and propensity techniques (32)
in which propensity score quintile was substituted for the
vector of independent variables except treatment, and alter-
nativelywheretherawpropensityscorewasusedasaweight.
It should be noted, however, that propensity techniques do
not account for unobserved confounding covariates (32).
Instrumental variable approaches have been applied to
S E E R - M e d i c a r ea n a l y s i s ,b u tt oo u rk n o w l e d g en o ti ns m a l l
cohorts such as ours.
A second limitation of this study is that we did not
include a comparator group of patients who did not receive
t r a s t u z u m a b .T h em a i nr e a s o ni st h a t ,p r e s e n t l y ,S E E R -
Medicare does not include information on HER2 status. It
can be inferred that any patient who received trastuzumab
h a dH E R 2o v e r e x p r e s s i n gd i s e a s e ,b a s e do nt h ef a c tt h a t
Medicare does not pay for trastuzumab without a positive
HER2 test result. However, it is not possible to identify
patients who are HER2 positive but who do not receive
trastuzumab. Since HER2 overexpression is a significant
predictor of both overall survival and time to relapse in
patients with breast cancer, (37) the absence of HER2 test
results is a significant barrier to conducting comparative ef-
fectiveness research (e.g. chemotherapy with versus without
trastuzumab) on trastuzumab using this database, because
o n ec a n n o ti d e n t i f yaH E R 2p o s i t i v ec o n t r o lg r o u p .S e c o n d ,
while trastuzumab was first approved by FDA in September
1998, (38) a Medicare reimbursement code specifically
for trastuzumab did not become effective until January 1,
2000. Therefore, we were unable to document the use of
trastuzumab during the first year following approval.
Third, as illustrated, patterns of trastuzumab use were di-
verse, ranging from long, uninterrupted periods with mul-
tiple administrations per month to short periods with only
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one administration per month. While this diversity makes it
difficult to assess the outcomes effects of trastuzumab under
“optimal use,” our analysis does reflect its impact in routine
clinical practice.
Fourth we used an algorithm based on Medicare claims
(15, 16) to identify distant recurrence (metastatic disease)
amongthosepatientswhowereinitiallydiagnosedwithStage
0–III disease. Although claims-based algorithms for identi-
fying relapse/recurrence have been validated in AML, (15)
theyhavenotbeenvalidatedinbreastcancer.Onestudycon-
ducted before the development of the algorithms for AML
found that Medicare claims within 3 months of the SEER
date of breast cancer diagnosis correctly identified only 60%
of those with distant Stage disease at diagnosis according to
SEER (39). One important difference, however, is that we
used claims to identify recurrence in those previously diag-
nosed and staged using SEER data.
Nevertheless, to gain additional insight on this issue, we
applied this algorithm to a much larger cohort of women in
SEER-Medicare who were diagnosed with early-Stage (stage
I–III) breast cancer, and who received adjuvant chemother-
apy. In this cohort, the cumulative rate of recurrence we
observed, approximately 30% after 4 years, was similar
to that for anthracycline- and CMF- (cyclophosphamide,
methotrexate, fluorouracil) based regimens for early breast
cancer in older women as reported by the Early Breast Can-
cer Trialists’ Collaborative Group (EBCTCG) (40). Also, the
distribution of sites of distant recurrence was consistent with
what has been previously reported.
Finally, we did not investigate the use of trastuzumab in
the adjuvant setting since it was not approved for this indica-
tion until 2006.
Despite the aforementioned limitations, to our knowl-
edge, this is the first study to describe the use of trastuzumab
for MBC in a large cohort of older women diagnosed with
breast cancer. It shows treatment patterns consistent with
t h el i t e r a t u r ep u b l i s h e da r o u n dt h et i m et r e a t m e n td e c i s i o n s
within the cohort were being made, but less consistent with
the product labeling. Also, aside from one recent trial dis-
cussed above (10), we are unaware of any other study, ob-
servational or experimental, comparing survival in patients
who receive trastuzumab alone versus in combination with
chemotherapy for MBC. Our findings suggest trastuzumab
in combination with chemotherapy is more effective than
trastuzumab alone when used as first-line therapy for MBC.
Since almost one-third of the first-line trastuzumab patients
inourcohortreceivedtrastuzumabalone,apotentialareafor
furtherresearchwouldbeinvestigatingthereasonsclinicians
andpatientsmightelecttousetrastuzumabmonotherapyin-
stead of trastuzumab plus chemotherapy.
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